Preservative-Free MK2452 (Tafluprost) for Open-Angle Glaucoma/Ocular Hypertension (MK2452-001)(COMPLETED)

This is an interventional treatment trial for Open-angle Glaucoma Read More

Inclusion Criteria:

• Patient has been diagnosed with primary open-angle glaucoma, pigmentary glaucoma, capsular glaucoma/pseudoexfoliation, or ocular hypertension
• Patient has a mean (or median) IOP of >=23 and =<36 in at least one eye at the 0800 hours time point at the Baseline Visit.
• Patient has <5 mmHg difference in mean (or median) IOP between eyes at each time point (0800 hours, 1000 hours, and 1600 hours) at Baseline.
• Patient is currently using a prescribed ocular hypotensive medication and has been on a stable dose for 30 days prior to screening, or patient is drug-naive (those who have never used or who have not used ocular hypotensive medication for at least 4 weeks prior to screening)
• Patient is able to safely discontinue current ocular hypotensive medication during up to the 4-week washout period
• Patient has vision corrected to 20/80 or better in each eye
• Patient is willing and able to avoid wearing contact lenses from 4 weeks prior to dosing through 24 hour after final dosing
• Patient is willing and able to self-administer or has an able person available on a daily basis to assist with administration of study medications
• Patient is not pregnant and not planning to become pregnant during the study
• Patient is male or female ≥18 of age on the day of signing the informed consent

Exclusion Criteria:

• Patient is unable to use study medication in the affected eye(s)
• Patient has a history of inflammatory ocular surface disease or anterior or posterior uveitis in either eye
• Patient has a history of retinal detachment, diabetic retinopathy, or other progressive retinal disease
• Patient has experienced significant visual field loss within the last year
• Patient has had intraocular surgery in either eye in the last 4 months
• Patient has a history of glaucoma surgery or refractive surgery in either eye
• Patient is currently taking two or more anti-glaucoma medications (except Cosopt™ or its generic formulation)
• Patient has previously used tafluprost
• Patient has a history of cardiovascular disorder within 6 months prior to screening
• Patient has a history of bronchial asthma, wheezing, pneumonia, COPD, other pulmonary disease, or abnormal chest x-ray
• Patient has a mean (or median) IOP >36 mmHg in either eye at the Screening Visit or at any time point (0800 hours, 1000 hours, and 1600 hours) of the Baseline Visit.